Your browser doesn't support javascript.
loading
Gain and loss of function variants in EZH1 disrupt neurogenesis and cause dominant and recessive neurodevelopmental disorders.
Gracia-Diaz, Carolina; Zhou, Yijing; Yang, Qian; Maroofian, Reza; Espana-Bonilla, Paula; Lee, Chul-Hwan; Zhang, Shuo; Padilla, Natàlia; Fueyo, Raquel; Waxman, Elisa A; Lei, Sunyimeng; Otrimski, Garrett; Li, Dong; Sheppard, Sarah E; Mark, Paul; Harr, Margaret H; Hakonarson, Hakon; Rodan, Lance; Jackson, Adam; Vasudevan, Pradeep; Powel, Corrina; Mohammed, Shehla; Maddirevula, Sateesh; Alzaidan, Hamad; Faqeih, Eissa A; Efthymiou, Stephanie; Turchetti, Valentina; Rahman, Fatima; Maqbool, Shazia; Salpietro, Vincenzo; Ibrahim, Shahnaz H; di Rosa, Gabriella; Houlden, Henry; Alharbi, Maha Nasser; Al-Sannaa, Nouriya Abbas; Bauer, Peter; Zifarelli, Giovanni; Estaras, Conchi; Hurst, Anna C E; Thompson, Michelle L; Chassevent, Anna; Smith-Hicks, Constance L; de la Cruz, Xavier; Holtz, Alexander M; Elloumi, Houda Zghal; Hajianpour, M J; Rieubland, Claudine; Braun, Dominique; Banka, Siddharth; French, Deborah L.
Afiliação
  • Gracia-Diaz C; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Zhou Y; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Yang Q; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Maroofian R; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Espana-Bonilla P; Department of Neuroscience and Mahoney Institute for Neurosciences, University of Pennsylvania, Philadelphia, PA, USA.
  • Lee CH; Department of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK.
  • Zhang S; Department of Structural and Molecular Biology, Instituto de Biología Molecular de Barcelona (IBMB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
  • Padilla N; Department of Biomedical Sciences and Pharmacology, Seoul National University, College of Medicine, Seoul, South Korea.
  • Fueyo R; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA.
  • Waxman EA; Research Unit in Clinical and Translational Bioinformatics, Vall d'Hebron Institute of Research (VHIR), Universitat Autonoma de Barcelona, Barcelona, Spain.
  • Lei S; Department of Structural and Molecular Biology, Instituto de Biología Molecular de Barcelona (IBMB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
  • Otrimski G; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Li D; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Sheppard SE; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Mark P; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Harr MH; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Hakonarson H; Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Rodan L; Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Jackson A; Department of Pediatrics, Division of Medical Genetics, Helen DeVos Children's Hospital, Corewell Health, Grand Rapids, MI, USA.
  • Vasudevan P; Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Powel C; Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Mohammed S; Department of Neurology, Boston Children's Hospital, Boston, MA, USA.
  • Maddirevula S; Division of Genetics & Genomics, Boston Children's Hospital, Boston, MA, USA.
  • Alzaidan H; Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
  • Faqeih EA; Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
  • Efthymiou S; Leicestershire Clinical Genetics Service, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK.
  • Turchetti V; Leicestershire Clinical Genetics Service, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK.
  • Rahman F; Guy's Hospital, London, UK.
  • Maqbool S; Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Salpietro V; Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Ibrahim SH; Section of Medical Genetics, Children's Specialist Hospital, King Fahad Medical City, Riyadh, Saudi Arabia.
  • di Rosa G; Department of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK.
  • Houlden H; Department of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK.
  • Alharbi MN; Developmental and Behavioral Pediatrics, University of Child Health Sciences & The Children's Hospital, Lahore, Pakistan.
  • Al-Sannaa NA; Developmental and Behavioral Pediatrics, University of Child Health Sciences & The Children's Hospital, Lahore, Pakistan.
  • Bauer P; Department of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK.
  • Zifarelli G; Department of Pediatrics and Child Health, Aga Khan University Hospital, Karachi, Pakistan.
  • Estaras C; Child Neuropsychiatry Unit, Department of Pediatrics, University of Messina, Messina, 98100, Italy.
  • Hurst ACE; Department of Neuromuscular Disorders, Queen Square Institute of Neurology, University College London, London, UK.
  • Thompson ML; Maternity and Children Hospital Buraidah, Qassim Health Cluster, Buraydah, Saudi Arabia.
  • Chassevent A; John Hopkins Aramco Health Care, Pediatric Services, Dhahran, Saudi Arabia.
  • Smith-Hicks CL; Centogene GmbH, Rostock, Germany.
  • de la Cruz X; Centogene GmbH, Rostock, Germany.
  • Holtz AM; Center for Translational Medicine, Department of Cardiovascular Sciences, Temple University, Philadelphia, PA, USA.
  • Elloumi HZ; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Hajianpour MJ; HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
  • Rieubland C; Department of Neurogenetics, Neurology and Developmental Medicine Kennedy Krieger Institute, Baltimore, MD, USA.
  • Braun D; Department of Neurogenetics, Neurology and Developmental Medicine Kennedy Krieger Institute, Baltimore, MD, USA.
  • Banka S; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA.
  • French DL; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Nat Commun ; 14(1): 4109, 2023 07 11.
Article em En | MEDLINE | ID: mdl-37433783
ABSTRACT
Genetic variants in chromatin regulators are frequently found in neurodevelopmental disorders, but their effect in disease etiology is rarely determined. Here, we uncover and functionally define pathogenic variants in the chromatin modifier EZH1 as the cause of dominant and recessive neurodevelopmental disorders in 19 individuals. EZH1 encodes one of the two alternative histone H3 lysine 27 methyltransferases of the PRC2 complex. Unlike the other PRC2 subunits, which are involved in cancers and developmental syndromes, the implication of EZH1 in human development and disease is largely unknown. Using cellular and biochemical studies, we demonstrate that recessive variants impair EZH1 expression causing loss of function effects, while dominant variants are missense mutations that affect evolutionarily conserved aminoacids, likely impacting EZH1 structure or function. Accordingly, we found increased methyltransferase activity leading to gain of function of two EZH1 missense variants. Furthermore, we show that EZH1 is necessary and sufficient for differentiation of neural progenitor cells in the developing chick embryo neural tube. Finally, using human pluripotent stem cell-derived neural cultures and forebrain organoids, we demonstrate that EZH1 variants perturb cortical neuron differentiation. Overall, our work reveals a critical role of EZH1 in neurogenesis regulation and provides molecular diagnosis for previously undefined neurodevelopmental disorders.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurogênese / Complexo Repressor Polycomb 2 / Transtornos do Neurodesenvolvimento Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurogênese / Complexo Repressor Polycomb 2 / Transtornos do Neurodesenvolvimento Idioma: En Ano de publicação: 2023 Tipo de documento: Article